Ayurveda Alone at the Gates: A Pandemic Thought Experiment

By Dr. Aakash Kembhavi

[This article was developed with AI assistance as part of the author’s committed practice of transparent human-AI collaboration in academic writing.]

“The best way to find out if you can trust somebody is to trust them.” — Ernest Hemingway

The best way to find out if a system of medicine is ready is to need it.

Preface: Why This Thought Experiment Matters

Imagine a virus. Novel, fast-moving, poorly understood. It spreads across continents before anyone has named it. Hospitals are overwhelmed. Governments are desperate. And in this particular scenario — bear with me — modern medicine either does not exist, or has explicitly stepped aside.

Ayurveda is at the gates. Alone.

Not as a supplement. Not as an immune booster being quietly administered alongside dexamethasone and oxygen. Not as a press release from the Ministry of AYUSH claiming that Chyawanprash reduces susceptibility. This time, Ayurveda is the system. It must diagnose, treat, advise, scale, and be accountable for outcomes — for a billion people, and potentially for the world.

This is not a hostile thought experiment. It is a sincere one. It is, in fact, the most respectful question one can ask of any system of medicine: Are you ready?

What follows is a structured walkthrough of that scenario, question by question. The answers — or more precisely, the places where answers are conspicuously absent — are the real argument of this article.

Step 1: The Outbreak Begins. What Are the First Steps?

In any genuine public health emergency, the first 72 hours are defined by surveillance, communication, and containment. The questions that must be answered immediately are: What is this? How does it spread? Who is most vulnerable?

Now ask those questions through an Ayurvedic lens.

What is this disease? In Ayurvedic epistemology, disease identification begins with Nidana Panchaka — the five-fold diagnostic framework of causative factors, prodromal symptoms, manifest symptoms, pathophysiological understanding, and therapeutic response as diagnostic confirmation. This is a rich framework for diseases the system has encountered and classified. For a novel pathogen — one that behaves in ways no Acharya has described — it is immediately strained.

Does this disease present as a Vataja Jwara? A Sannipataja condition? A new variant of Vishama Jwara? Different senior Vaidyas will answer differently, and there is no agreed rapid-assessment protocol that can be deployed in the field within hours.

More fundamentally: Ayurveda has no equivalent of the WHO’s International Health Regulations, no epidemic intelligence surveillance network, no disease notification system, and no emergency response SOP that has been pre-drafted, pre-tested, and pre-authorised. This is not a criticism unique to Ayurveda — but it is a fact that cannot be glossed over. The first step in this scenario is not a clinical decision. It is the recognition that the infrastructure for even framing the emergency in actionable terms does not currently exist.

That is what the first 72 hours would reveal. And it would cost lives.

Step 2: Who Represents Ayurveda? Who Gets the Call?

Every crisis needs a command structure. When COVID-19 struck, governments called their Chief Medical Officers, their epidemiologists, their ICU specialists. The credentialing question answered itself, because the specialisation matched the crisis.

Now imagine the call going to Ayurveda. Who picks up?

The CCRAS Director? A senior Professor of Kaya Chikitsa from one of the top institutions? The AYUSH Secretary? A celebrated practitioner with thirty years of clinical experience but no research publications? The editor of a respected Ayurvedic journal? The Rajyavaidya with political proximity to the health ministry?

All of these people exist. All of them would, legitimately and sincerely, consider themselves qualified to represent Ayurveda in a crisis. And that is precisely the problem.

There is no pre-established, criteria-based emergency expert committee for Ayurveda. There is no Indian equivalent of SAGE — the Scientific Advisory Group for Emergencies that the UK Government convened during COVID-19, whose membership criteria, conflict-of-interest declarations, and decision-making protocols were pre-defined. In the absence of such a structure, what fills the vacuum is a combination of institutional seniority, political access, and reputational prestige — none of which are the same as crisis-relevant competence.

The first battle in a pandemic response, then, would not be against the virus. It would be a turf war among experts.

Step 3: What Credentials Should These Experts Hold?

This question deserves its own section because it exposes a fault line that runs through Ayurvedic academia: the gap between credential and competence.

An MD Ayurveda degree in India today is awarded by universities whose entry standards, faculty quality, dissertation rigour, and examination integrity vary so dramatically that two people holding the same parchment may inhabit entirely different epistemic universes. One has spent three years conducting a carefully designed clinical study with statistical analysis and ethics committee oversight. Another has submitted a literature review-dressed-as-research that was approved because institutional survival demanded it.

Both are MD (Ayu).

In a pandemic response expert committee, what credentials would actually matter? Consider what the role demands: the ability to evaluate evidence under uncertainty; the ability to design rapid observational studies or adaptive trials; the ability to communicate uncertainty to the public without either catastrophising or minimising; the ability to integrate incoming clinical data from multiple sites and update recommendations accordingly; and the willingness to say — loudly, on record — this is not working, we need to change course.

How many Ayurvedic experts, assessed honestly and without institutional courtesy, meet all five criteria?

The credential system as it currently stands cannot answer that question. And a pandemic cannot wait for the answer to be negotiated.

Step 4: How Will They Proceed? What Is the Process?

Assume, generously, that a competent committee has been assembled. What happens next?

In evidence-based medicine, crisis protocol development follows a defined sequence: rapid evidence synthesis from existing literature → expert consensus → draft guideline → field testing → revision → dissemination → monitoring. Each step has defined inputs, outputs, and timelines. The process is imperfect under pressure, but it is a process.

What is Ayurveda’s equivalent process?

There is no formal rapid evidence synthesis mechanism for Ayurvedic literature. The classical texts — Charaka Samhita, Sushruta Samhita, Ashtanga Hridayam and their commentaries — contain rich clinical observations, but extracting evidence relevant to a novel disease requires interpretive scholarship that is simultaneously deeply subjective and time-consuming. Two Samhita scholars of equal standing may arrive at contradictory conclusions about which classical disease category applies to a new presentation, and there is no tiebreaker.

The CCRAS has conducted clinical research and maintains a repository of studies. But this repository does not constitute a graded evidence base of the kind that clinical guideline development requires. The studies are heterogeneous in design, inconsistent in outcome measures, and largely unpublished in internationally indexed peer-reviewed journals — not because Ayurvedic research is inherently inferior, but because the system has not invested in building the infrastructure to produce and preserve evidence in crisis-deployable form.

The proceeding, then, would likely be a series of expert meetings dominated by the most assertive voices, arriving at a consensus that reflects the political equilibrium of the room more than the weight of clinical evidence. This is not cynicism. This is the institutional sociology of any under-prepared system under pressure. And Ayurveda, however rich its heritage, is institutionally under-prepared for this.

Step 5: What Prior Evidence Will They Consult? Samhita References and Clinical Guidelines

This is the question that Ayurvedic experts will answer with the most confidence — and it is the question that most requires scrutiny.

The Samhitas do contain descriptions of epidemic disease. The concept of Janapadodhvamsa — the destruction of communities — in Charaka Samhita’s Vimana Sthana is one of the most sophisticated early discussions of epidemic causation in any medical tradition. It considers environmental degradation, contamination of air, water, land, and seasons as causative factors, and anticipates what we would now call social determinants of disease. This is genuinely impressive.

But there are several problems with leaning on Samhita references as a primary crisis response framework.

First, the diseases described were observed and recorded in a specific epidemiological context — pre-industrial, pre-urbanisation, without the microbial taxonomy we now possess. Applying these descriptions to a novel RNA virus spreading through aerosol transmission in a hyper-connected global population requires interpretive leaps that cannot be objectively validated.

Second, the therapeutic recommendations in the context of Janapadodhvamsa are largely prophylactic and constitutional — Rasayanas, lifestyle modifications, Achara Rasayana. These are valuable for population-level health maintenance. They are not a treatment protocol for an acutely deteriorating patient with cytokine storm-equivalent pathophysiology.

Third, there are no dose-standardisation data in classical texts of the kind required for mass treatment protocols. Formulation proportions, processing methods, adjuvants, dosage by body weight and disease severity, contraindications in hepatic or renal compromise, interactions with other substances — these are either absent or expressed in units and concepts that require significant translation before they can be operationalised at scale.

The Samhitas are a beginning. They are not a protocol. Treating them as equivalent to clinical practice guidelines — as is sometimes done in the enthusiasm of crisis response — is not respect for tradition. It is a misuse of tradition that tradition itself would not sanction.

Step 6: How Will Standard Medicines Be Advised?

Let us say the committee reaches consensus on a treatment protocol. It recommends, for instance, a combination of Giloy Ghanvati, Trikatu Churna, Samshamani Vati, and a specific classical decoction for mild-to-moderate cases, with a Rasayana for recovery. This is not a fictitious scenario — variants of this were, in fact, recommended during COVID-19.

The questions that must now be answered before this becomes a national protocol are as follows.

What is the standard dose? For whom? A 60 kg adult and a 90 kg adult receive the same Giloy Ghanvati tablet because it is a fixed-dose manufactured form — but was the dose determined by clinical evidence or by manufacturing convention?

What is the contraindication profile? Giloy (Tinospora cordifolia) has been associated with hepatotoxicity in some published case reports. In a population of millions, including people with pre-existing liver disease, alcoholic liver disease, and those on hepatotoxic drugs, this is not a footnote. It is a safety signal that demands a formal risk stratification framework before mass recommendation.

What are the drug interactions? If patients — as they inevitably will in India’s real-world health landscape — are simultaneously taking antihypertensives, antidiabetics, or anticoagulants, are there documented interaction profiles? The honest answer is: largely no. Not in the form that a prescribing physician making a bedside decision can rely upon.

Who manufactures the recommended formulations? Under what GMP standards? With what batch-to-batch quality consistency? The Indian pharmaceutical landscape for Ayurvedic medicines includes manufacturers ranging from WHO-GMP-certified facilities to backyard operations with no quality control whatsoever — and the recommended formulation will be sought from all of them simultaneously once a national advisory is issued.

Advising on standard medicines, in other words, is not one decision. It is a hundred decisions, each of which requires infrastructure that is currently absent, partial, or uncoordinated.

Step 7: What Clinical Guidelines Will Be Provided to Practitioners?

A guideline is only as good as the practitioner who receives and implements it. And here, Ayurveda faces perhaps its most sobering challenge.

India has approximately 600,000 registered AYUSH practitioners. Their training spans institutions ranging from the genuinely excellent to the frankly scandalous. Their clinical exposure ranges from sophisticated hospital settings to solo rural practice with no diagnostic support. Their familiarity with research evidence ranges from rigorous to non-existent. Their access to continuing medical education is episodic at best.

A clinical guideline issued from New Delhi will be received by this enormously heterogeneous workforce. How will it be communicated? How will it be explained? How will it be updated when the evidence changes? How will compliance be monitored?

Modern medicine handles this imperfectly but has infrastructure for it: professional bodies, specialty colleges, hospital formularies, drug information centres, and — crucially — a workforce trained in the language of evidence-based medicine that allows guidelines to be read critically rather than simply obeyed.

Ayurveda does not yet have equivalent dissemination infrastructure. What it has is a culture of authority-based practice, where the recommendation of a senior figure carries more weight than the quality of the evidence behind it. In a stable clinical environment, this is a manageable limitation. In a fast-moving pandemic where guidelines must be updated frequently as new data emerges, it is a structural liability.

A guideline that cannot be consistently understood, consistently implemented, consistently monitored, and consistently revised is not a guideline. It is a press release.

Step 8: What If It Doesn’t Work? The Course-Correction Problem

This is the question that should keep every Ayurvedic authority awake at night — and the one that is most rarely asked.

In evidence-based medicine, a treatment protocol that is not working generates a signal. Outcomes data from multiple sites, compiled and analysed in near-real time, shows that mortality or morbidity is not improving as expected. This signal triggers a protocol review. The review may lead to modification, discontinuation, or replacement of the recommended treatment. The process is painful, politically fraught, and often delayed — but it exists. It is built into the architecture of the system.

What is Ayurveda’s equivalent mechanism?

For a course-correction to occur, three things must be true. First, outcomes must be systematically collected — which requires standardised case reporting across thousands of practitioners, a data management infrastructure, and a biostatistical analysis capacity. Second, the collected outcomes must be interpreted without motivated reasoning — which requires an independent evaluation process insulated from the institutional and political interests of those who recommended the original protocol. Third, the decision to change course must be communicated and implemented rapidly — which requires the dissemination infrastructure described above.

None of these three conditions are currently met in Ayurveda’s institutional architecture.

What actually happens, historically, when an Ayurvedic recommendation proves ineffective? The answer tends to be one of several things: the cases are attributed to constitutional factors in the patient rather than inadequacy of the protocol; the dosage or adjuvant is adjusted based on individual practitioner intuition; the formulation is supplemented with additional medicines; or — most troublingly — the ineffectiveness is attributed to incorrect diagnosis and the protocol is retrospectively declared correct for the disease it was actually meant to treat.

None of these are course-correction. They are immunisation against the recognition that course-correction is needed. And in a pandemic, that immunisation is lethal.

Step 9: The Diagnostic Challenge — What Is This Disease, Really?

This question deserves separate treatment because it precedes all the others, even though its implications only become clear as the scenario unfolds.

Will the expert committee accept modern diagnostic tools — PCR tests, serological assays, CT imaging, blood biomarkers — as part of the clinical framework? If yes, on what epistemic basis? Ayurveda’s diagnostic framework was not constructed to interface with molecular diagnostic data. Accepting these tools without a coherent framework for integrating them into Ayurvedic clinical reasoning creates a hybrid that is neither good modern medicine nor good Ayurveda.

If the committee rejects modern diagnostics in favour of purely Ayurvedic assessment tools — pulse diagnosis, physical examination, symptom pattern recognition — then it must accept that in a disease with significant asymptomatic spread and in patients whose presentations defy classical symptom clusters, the diagnostic accuracy will be systematically compromised.

And what happens when two senior Vaidyas examining the same patient arrive at different Nidana assessments? In routine clinical practice, this is a professional disagreement. In a pandemic protocol, it is a system failure. There is no Ayurvedic equivalent of the differential diagnosis algorithm — the structured decision tree that forces clinical reasoning to confront its own uncertainty and work through it systematically.

The diagnostic challenge is not a failure of Ayurvedic theory. It is a failure of Ayurvedic institutional investment in translating that theory into operational tools that can function reliably across a heterogeneous practitioner workforce.

Step 10: The Expert Disagreement Problem — Who Adjudicates?

Assume the scenario has been running for three weeks. The committee has issued guidelines. Two of the most respected names in Ayurveda — one from the Kerala tradition, one from the North Indian institutional mainstream — have publicly disagreed on the core formulation. One endorses a Vata-pacifying approach; the other argues the presentation is primarily Pitta-dominant and the recommended protocol is actively contraindicated.

Both have published extensively. Both have decades of clinical experience. Both have large followings within the profession. Both are sincere.

Who decides?

This is not a hypothetical edge case. Disagreement among traditions and schools of Ayurveda is not occasional — it is foundational. The Brihattrayi texts themselves differ on significant points of classification and management. The classical commentators disagree with each other. The Kerala Ayurvedic tradition has distinct practices from the pan-Indian textbook consensus. Regional variations in formulation, processing, and emphasis are a feature of the tradition, not a bug.

In a stable clinical context, this pluralism is one of Ayurveda’s genuine strengths — it allows individualised, contextually sensitive care. In a pandemic requiring a single national protocol, it is a governance crisis. And Ayurveda currently has no governance mechanism — no Supreme Clinical Council, no protocol arbitration process, no graded evidence hierarchy — that can resolve this crisis with legitimate authority rather than raw institutional power.

The danger is not that the disagreement will occur. The danger is that it will be resolved by political seniority rather than clinical reason, and that the resolution will be presented to the public as Ayurvedic consensus when it is, in fact, Ayurvedic negotiation.

Step 11: Supply, Quality, and the Medicines That Reach People

Suppose the protocol is finalised, disseminated, and accepted. A nation of 1.4 billion people — plus international demand — now requires specific Ayurvedic formulations in quantities that the current manufacturing ecosystem has never been asked to produce.

What happens?

The GMP-certified, quality-controlled manufacturers scale up as fast as they can. But demand outstrips their capacity within days. Into the gap pour the second-tier and third-tier manufacturers: some reputable, many not. Formulations are adulterated, proportions are altered, raw material substitutions are made because the authentic ingredient is out of stock. Heavy metal preparations — Rasa Aushadhas — are manufactured without proper Shodhana processing because the time-intensive traditional purification protocols cannot be compressed to meet emergency timelines.

The medicines that reach patients across India will carry the same names as the recommended formulations. They will not all be the same medicines.

This is not speculation. It is an extrapolation from the documented reality of the Indian Ayurvedic pharmaceutical market, where quality control compliance is inconsistent, post-market surveillance is minimal, and the Pharmacovigilance Programme for Ayurveda (ASU&H PvPI) — though it exists — operates at a scale and sensitivity that is frankly inadequate for routine conditions, let alone an emergency.

Who is responsible for the patients harmed by a substandard Ashwagandha preparation, or by a Rasa Aushada with inadequate detoxification? The manufacturer? The prescribing physician? The expert committee that recommended the formulation without simultaneously mandating quality standards for its procurement? The ministry that issued the advisory without a supply-chain integrity plan?

The answer, in the absence of a clear accountability framework, is: no one. And no one is an answer that a pandemic cannot tolerate.

Step 12: When Patients Die — Accountability, Documentation, and Moral Responsibility

This is the hardest question in the scenario. It is also the most important.

Patients will die. In any epidemic of sufficient scale, some patients will die regardless of what treatment they receive — because disease can exceed the capacity of any medical system to save every life. This is true of modern medicine. It would be true of Ayurveda. Death in the context of a medical protocol is not, by itself, evidence of protocol failure.

But some patients will die because the protocol was wrong. Some will die because the medicines they received were substandard. Some will die because the guideline was not updated quickly enough when the evidence changed. Some will die because a contraindicated formulation was given to a patient whose profile should have excluded them, but the contraindication was never formally documented.

When this happens, who is accountable?

Modern medicine has imperfect but real mechanisms: medical error reporting systems, adverse event documentation requirements, inquest and coroner processes, malpractice liability, and — at the system level — formal after-action reviews that attempt to learn from failure. These mechanisms are imperfect and frequently subverted by institutional self-protection. But they exist, and their existence creates at least a cultural expectation of accountability.

What are Ayurveda’s equivalent mechanisms? The Consumer Protection Act applies to all medical practitioners, including AYUSH. But the clinical and forensic infrastructure for establishing causation between an Ayurvedic protocol and a patient death is essentially nonexistent. There is no standardised adverse event reporting requirement for Ayurvedic practitioners. There is no database of protocol-associated deaths that can generate learning. There is, frankly, no culture of systematic clinical failure analysis within Ayurvedic institutions.

The moral weight of this is significant. To ask Ayurveda to take sole responsibility for a pandemic response without simultaneously demanding that it build the accountability architecture that such responsibility requires is not respect for Ayurveda. It is a setup for a moral catastrophe that the tradition does not deserve and that patients cannot survive.

Step 13: The International Dimension — Ayurveda at the WHO Table

If this is a global pandemic, the expert committee must eventually face the international community. WHO will ask for a data package. Other nations will ask: on what evidence is this protocol based? What are the outcomes data?

Ayurveda has two choices at this point, and neither is comfortable.

Choice one: present evidence on its own epistemological terms — classical textual references, expert consensus, observational case series, traditional use documentation. This will be received by the international community with polite incomprehension at best and dismissive scepticism at worst. It will not meet the evidentiary threshold for a WHO Emergency Use Listing. Ayurveda will be relegated to a footnote.

Choice two: submit to RCT-based evidentiary standards, rapidly design and conduct Phase II/III clinical trials in the middle of a pandemic, and seek international validation on modern medicine’s terms. This may gain acceptance — but it concedes the epistemological argument that Ayurveda has been making for decades, namely that its knowledge system requires different but equally valid evidentiary frameworks. It also requires statistical and trial management expertise that most Ayurvedic institutions do not currently possess in-house.

There is, theoretically, a third choice: an internationally negotiated pluralistic evidentiary framework that gives Ayurvedic evidence appropriate but conditional weight. This would require years of prior diplomatic and scientific groundwork with WHO, ICMR, and international partners.

That groundwork has not been done.

Coda: The Audit Is Not the Accusation

At this point, a reader sympathetic to Ayurveda may feel that this thought experiment has been constructed to humiliate the tradition. It has not. The argument here is not that Ayurveda has nothing to offer in a pandemic. During COVID-19, there is genuine — if preliminary — evidence that certain Ayurvedic interventions contributed to symptom management and immune support. Practitioners with deep clinical experience made real contributions at the ground level. The tradition’s holistic orientation toward host resistance, rather than purely pathogen-directed therapy, is a philosophically legitimate alternative lens.

The argument is simpler and more demanding than outright dismissal: that the gap between Ayurveda’s clinical heritage and Ayurveda’s institutional readiness to exercise sole responsibility for a pandemic response is not a gap that can be bridged by confidence, conviction, or classical quotation.

It requires — urgently, systematically, and without further excuse — the construction of: a credentialing architecture that matches competence to crisis-relevant roles; a rapid evidence synthesis infrastructure; a pharmacovigilance system adequate to population-scale interventions; a supply chain with mandatory quality enforcement; a clinical guideline dissemination mechanism; a course-correction protocol with falsifiability built in; and an accountability framework with genuine moral weight.

None of these are alien to Ayurveda. All of them are compatible with Ayurveda’s philosophical foundations. Many of them are, in embryonic form, already present in initiatives like CCRAS, the ASU&H PvPI, the National Pharmacopoeia Commission, and the NCISM.

The question is not whether Ayurveda can build this architecture. The question — and the one this thought experiment was always really asking — is whether Ayurveda’s institutions, authorities, and leaders have the will, the honesty, and the urgency to build it before the next pandemic knocks at the gates.

Because the gates, as history has demonstrated with ruthless regularity, do not wait.

The author welcomes critical engagement, disagreement, and counter-arguments from practitioners, researchers, and policymakers within the Ayurvedic community. The purpose of this article is interrogation, not indictment.

Share your thoughts in the comments below.